View Cart  

Oct. 26, 2012

Vol. 9 No. 211

View Archived Issues

Sign Up Now

FDA Lays Out Some Fiscal 2013 Generic Drug User Fee Rates; ANDAs to Cost About $50K

ANDA filers that have submitted an application on or after Oct. 1 must pay $51,520 in user fees, according to the FDA’s 2013 generic drug user fee rates announced Wednesday. Read More

EU, Israel Could Ease Trade Barriers

The International Trade Committee last month narrowly endorsed a mutual recognition deal that would allow EU-certified medicines to be exported to Israel and vice-versa without requiring additional certification for the importing country. Read More

FDA Sets Feb. 5 Date for Avastin’s Colon Cancer sBLA

The FDA has granted a priority review to Genentech’s sBLA for Avastin in people with metastatic colorectal cancer (mCRC) who have already been treated with chemotherapy plus Avastin. Read More

Lupin Gets FDA Final Nod to Market Generic Seasonale Tablets

Lupin Pharmaceuticals received final approval for its levonorgestrel and ethinyl estradiol tablets, USP 0.15 mg/0.03 mg, from the FDA to market a generic version of Teva Pharmaceuticals’ Seasonale tablets. Read More

Novel Drug Stars in Phase III PAH Trial

Macitentan, an investigational next-generation endothelin receptor antagonist for pulmonary arterial hypertension (PAH), met its efficacy endpoint and was well tolerated in a large clinical trial. Read More

Tonix PK Study Confirms Effectiveness of TNX-102 Sublingual Tablet

Tonix Pharmaceuticals has completed dosing and plasma analysis of a pharmacokinetic (PK) study of its TNX-102 sublingual tablet, a formulation of cyclobenzaprine for bedtime use. Read More

Drugmakers Battle Over Suboxone Market

A generic drugmaker has accused a British pharmaceutical company of putting profits ahead of patients in its efforts to block cheaper generic versions of Suboxone from coming on the U.S. market. Read More

Germany Orders Recall of Some Novartis Flu Shots

German authorities ordered a recall Thursday of some batches of Novartis flu vaccine as a precautionary measure, after the company reported the appearance of small particles in the manufacturing process. Read More

New CEO Has Work Cut Out as AstraZeneca Sales Fall

AstraZeneca’s sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker’s new chief executive, Pascal Soriot. Read More